GO:0042159 lipoprotein catabolic process: Breakdown Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042159 (lipoprotein catabolic process) describes the biochemical breakdown of conjugated, water-soluble proteins whose covalently attached nonprotein group is a lipid or lipids.
• Lipoprotein catabolism is initiated by lipolytic enzymes and receptor-mediated endocytosis, delivering lipids and apolipoproteins to peripheral tissues and the liver.
• Key molecular players include LPL, hepatic lipase, LDLR, LRP1, APOB, APOE, and ANGPTL3/4/8, which regulate triglyceride-rich lipoprotein clearance.
• Dysregulation of lipoprotein catabolism contributes to atherosclerosis, dyslipidemias, and cardiometabolic disease, making it a major therapeutic target.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of genes in this pathway.
• Research methods include lipid flux assays, receptor-binding studies, transcriptomics, proteomics, and CRISPR library screening.
Description
Lipoprotein catabolic process (GO:0042159) is the biological process by which conjugated, water-soluble proteins carrying covalently attached lipids are broken down. This process is central to lipid homeostasis because it controls the clearance of triglyceride-rich lipoproteins and cholesterol-rich particles from circulation, delivering fatty acids and cholesterol to tissues. The ontology term encompasses both extracellular lipolytic remodeling and intracellular degradation following receptor-mediated endocytosis. Researchers study GO:0042159 to understand how genetic and environmental factors alter lipoprotein clearance and to identify therapeutic targets for cardiovascular and metabolic diseases. The process is highly regulated by apolipoproteins, lipases, and endocytic receptors, and its dysfunction is linked to atherosclerosis and dyslipidemias.
lipoprotein catabolic process At A Glance
| GO ID | GO:0042159 |
|---|---|
| GO term | lipoprotein catabolic process |
| Ontology | biological_process |
| Synonym | lipoprotein breakdown; lipoprotein catabolism; lipoprotein degradation |
| Major function | Breakdown of conjugated, water-soluble proteins with covalently attached lipids, enabling lipid clearance and tissue delivery |
| Key enzymes | Lipoprotein lipase (LPL), hepatic lipase (LIPC), endothelial lipase (LIPG) |
| Key receptors | LDL receptor (LDLR), LDL receptor-related protein 1 (LRP1), scavenger receptors |
| Regulatory proteins | ANGPTL3, ANGPTL4, ANGPTL8, apolipoproteins (APOB, APOE, APOC) |
| Cellular locations | Extracellular space, cell surface, endosomes, lysosomes |
What Is GO:0042159?
According to QuickGO, GO:0042159 (lipoprotein catabolic process) is defined as the chemical reactions and pathways resulting in the breakdown of any conjugated, water-soluble protein in which the covalently attached nonprotein group consists of a lipid or lipids. In simpler terms, it is the set of biochemical steps that degrade lipoproteins, which are lipid-protein complexes that transport fats in the bloodstream. This includes the hydrolysis of triglycerides and phospholipids by lipases, the remodeling of surface components, and the endocytic uptake and lysosomal degradation of lipoprotein particles.
Why Is lipoprotein catabolic process Important in Cell Biology?
Lipoprotein catabolic process is essential for maintaining plasma lipid levels and preventing the accumulation of atherogenic particles. Defects in this pathway cause familial hypercholesterolemia, hypertriglyceridemia, and increased cardiovascular risk. Understanding its molecular mechanisms informs the development of lipid-lowering therapies, including ANGPTL3 inhibitors and PCSK9-targeted approaches. Moreover, lipoprotein catabolism intersects with endosomal trafficking and lipid droplet turnover, linking it to broader cellular lipid homeostasis.
• Maintains plasma cholesterol and triglyceride homeostasis by clearing lipoproteins.
• Prevents atherosclerosis by removing atherogenic LDL and remnant particles.
• Regulates energy delivery to muscle and adipose tissue via fatty acid release.
• Dysregulation causes familial hypercholesterolemia and hypertriglyceridemia.
• Provides targets for lipid-lowering drugs (e.g., ANGPTL3, PCSK9).
• Links to endosomal trafficking and lipid droplet catabolism.
• Influences hepatic lipid handling and very-low-density lipoprotein secretion.
• Modulated by hormones and nutritional status, affecting metabolic disease risk.
What Happens During lipoprotein catabolic process?
Lipolytic Remodeling of Lipoproteins
In simple terms: Enzymes on blood vessel walls cut triglycerides inside lipoproteins, shrinking the particles.
The first step in lipoprotein catabolism is the hydrolysis of core triglycerides by lipoprotein lipase (LPL) anchored to endothelial cells, releasing free fatty acids for tissue uptake. Hepatic lipase (LIPC) and endothelial lipase (LIPG) further remodel remnant lipoproteins and HDL by hydrolyzing triglycerides and phospholipids. This lipolytic processing converts large triglyceride-rich lipoproteins into smaller remnant particles that are either taken up by the liver or further catabolized.
Receptor-Mediated Endocytosis
In simple terms: Cells grab lipoproteins from the blood using surface receptors and pull them inside.
Remnant lipoproteins and LDL are recognized by cell-surface receptors such as LDLR and LRP1, which mediate their internalization via clathrin-coated pits. Apolipoprotein E (APOE) and apolipoprotein B (APOB) serve as ligands for these receptors, directing particles to hepatocytes and peripheral cells. Endocytosis delivers the lipoprotein to endosomes, where the particle is sorted for lysosomal degradation or recycling.
Endosomal Sorting and Lysosomal Degradation
In simple terms: Inside the cell, lipoproteins are sent to recycling compartments or to lysosomes for breakdown.
After internalization, lipoproteins traffic through early endosomes to late endosomes/lysosomes, where acid lipases and proteases degrade the lipid and protein components. Cholesterol esters are hydrolyzed by lysosomal acid lipase (LIPA), freeing cholesterol for cellular use or excretion. Endosomal trafficking also participates in lipid droplet catabolism, linking lipoprotein degradation to intracellular lipid homeostasis.
Regulation by ANGPTL Proteins
In simple terms: Special proteins act as brakes or accelerators on the enzymes that break down lipoproteins.
ANGPTL3, ANGPTL4, and ANGPTL8 are key regulators of lipoprotein catabolism by inhibiting LPL activity in a tissue-specific manner. ANGPTL4 inhibits LPL in adipose tissue during fasting, while ANGPTL3 and ANGPTL8 regulate LPL in liver and oxidative tissues. Genetic loss of ANGPTL3 reduces plasma triglycerides and LDL cholesterol, validating this pathway as a therapeutic target.
Hormonal and Metabolic Control
In simple terms: Hormones and metabolic state change how fast lipoproteins are broken down.
Insulin, estrogens, and thyroid hormones modulate lipoprotein catabolism by altering lipase expression and receptor activity. Lipoprotein-associated estrogens can influence vascular lipid handling and atherogenesis. In chronic kidney disease, altered lipoprotein metabolism contributes to dyslipidemia and cardiovascular risk.
Key Genes Involved in GO:0042159 lipoprotein catabolic process
The following genes and proteins are central to lipoprotein catabolic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LPL | Hydrolyzes triglycerides in chylomicrons and VLDL | Rate-limiting enzyme; target for hypertriglyceridemia |
| LIPC | Hepatic lipase; remodels remnants and HDL | Affects HDL and remnant clearance |
| LIPG | Endothelial lipase; phospholipase activity on HDL | Modulates HDL catabolism |
| LDLR | Receptor for LDL and remnant uptake | Mutations cause familial hypercholesterolemia |
| LRP1 | Multifunctional receptor for remnant lipoproteins | Mediates hepatic clearance of remnants |
| APOB | Structural apolipoprotein of LDL and VLDL | Ligand for LDLR; target in dyslipidemia |
| APOE | Ligand for LDLR and LRP1 | Key for remnant clearance; linked to Alzheimer's risk |
| APOC2 | Activator of LPL | Deficiency causes hypertriglyceridemia |
| APOC3 | Inhibitor of LPL and hepatic remnant uptake | Target for antisense therapy |
| ANGPTL3 | Inhibits LPL and endothelial lipase | Loss-of-function lowers LDL and triglycerides |
| ANGPTL4 | Inhibits LPL in adipose tissue | Regulates fatty acid uptake during fasting |
| ANGPTL8 | Regulates ANGPTL3 activity | Modulates triglyceride clearance |
| LIPA | Lysosomal acid lipase; hydrolyzes cholesteryl esters | Deficiency causes Wolman disease and CESD |
| PCSK9 | Promotes LDLR degradation | Target of lipid-lowering antibodies and siRNA |
| SCARB1 | Scavenger receptor BI; mediates HDL uptake | Regulates reverse cholesterol transport |
| CETP | Transfers cholesteryl esters between lipoproteins | Modulates HDL and LDL catabolism |
| IDOL | E3 ubiquitin ligase that degrades LDLR | Regulates LDLR abundance |
How Is lipoprotein catabolic process Regulated?
Lipoprotein catabolic process is regulated at multiple levels. ANGPTL3, ANGPTL4, and ANGPTL8 control LPL activity in a tissue-specific and nutritional-state-dependent manner. Insulin and estrogens modulate lipase and receptor expression, influencing clearance rates. Intracellularly, endosomal trafficking and lysosomal function determine the efficiency of lipoprotein degradation. The E3 ubiquitin ligase IDOL promotes LDLR degradation, thereby reducing LDL uptake. These regulatory layers ensure tight control of plasma lipid levels and are disrupted in metabolic diseases.
lipoprotein catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDLR | Familial hypercholesterolemia | Knockout mouse, point-mutation knock-in |
| APOB | Familial hypercholesterolemia, dyslipidemia | Knock-in mouse, overexpression |
| LPL | Hypertriglyceridemia, chylomicronemia | Knockout mouse, tissue-specific KO |
| LIPA | Wolman disease, CESD | Knockout mouse, point-mutation knock-in |
| APOE | Alzheimer's disease, dyslipidemia | Knock-in mouse (human APOE isoforms) |
Atherosclerotic Cardiovascular Disease
Impaired lipoprotein catabolism leads to accumulation of atherogenic LDL and remnant particles, driving plaque formation. Genetic variants in LDLR, APOB, and PCSK9 cause familial hypercholesterolemia and premature coronary artery disease. ANGPTL3 inhibition lowers atherogenic lipids and is being explored as a therapeutic strategy.
Hypertriglyceridemia and Metabolic Syndrome
Defects in LPL, APOC2, or APOC3 cause severe hypertriglyceridemia due to reduced lipolysis of triglyceride-rich lipoproteins. Insulin resistance increases ANGPTL4 and reduces LPL activity, contributing to diabetic dyslipidemia. These abnormalities increase pancreatitis and cardiovascular risk.
Lysosomal Acid Lipase Deficiency
Mutations in LIPA cause Wolman disease and cholesteryl ester storage disease, characterized by massive accumulation of cholesteryl esters and triglycerides in lysosomes. This highlights the importance of lysosomal degradation in lipoprotein catabolism.
Neurodegeneration and APOE
APOE isoforms differentially affect lipoprotein catabolism and amyloid-beta clearance, influencing Alzheimer's disease risk. Impaired endosomal trafficking of lipoproteins has been linked to neuronal lipid dyshomeostasis.
From lipoprotein catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of gene X impair lipoprotein clearance? | CRISPR knockout cell line or mouse |
| Does a patient variant alter receptor binding? | Point-mutation knock-in |
| Can a therapeutic transgene restore catabolism? | Knock-in or overexpression |
| Where is the protein localized during catabolism? | Tagged knock-in (e.g., GFP, HA) |
| Which genes regulate lipoprotein uptake? | CRISPR library screening |
| How does gene X affect global lipid flux? | Overexpression and lipidomics |
How to Study the lipoprotein catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipoprotein clearance assay | Rate of lipoprotein removal from circulation | In vivo KO/overexpression studies |
| Cellular uptake assay | Internalization of labeled lipoproteins | Receptor function and variant testing |
| RNA-seq | Transcriptional changes in lipid genes | Pathway analysis after CRISPR perturbation |
| Proteomics | Protein abundance and modifications | Identifying novel regulators |
| Live-cell imaging | Endosomal trafficking and lysosomal delivery | Mechanistic studies of catabolism |
| CRISPR library screen | Genes affecting lipoprotein uptake | Discovery of new therapeutic targets |
| Lipidomics | Lipid species and quantification | Metabolic phenotyping |
| Immunoblotting | Protein levels of LDLR, LPL, etc. | Validation of knockout/overexpression |
Lipid Flux and Clearance Assays
Radioactive or fluorescently labeled lipoproteins are used to measure clearance rates in vivo and uptake in cultured cells. These assays quantify the functional impact of genetic perturbations on lipoprotein catabolism.
Transcriptomics and Proteomics
RNA-seq and mass spectrometry reveal changes in lipase, receptor, and apolipoprotein expression upon genetic manipulation. Proteomic profiling of lipoprotein fractions identifies novel regulators.
Imaging and Trafficking Studies
Fluorescence microscopy and live-cell imaging track endosomal trafficking of lipoproteins and their co-localization with lysosomal markers. These methods visualize the intracellular steps of catabolism.
CRISPR Library Screening
Genome-wide CRISPR knockout or activation screens identify genes that modulate lipoprotein uptake or degradation. Hits are validated by targeted knockout and functional assays.
How CRISPR Can Be Used to Study GO:0042159 lipoprotein catabolic process
Knockout
CRISPR knockout of candidate genes (e.g., LDLR, LPL, ANGPTL3) in cell lines or mice abolishes protein function, enabling assessment of their role in lipoprotein catabolism. Knockout models are used to measure changes in lipoprotein clearance and lipid accumulation.
Point Mutation
Point-mutation knock-in introduces patient-specific variants (e.g., in LDLR or APOB) to study their impact on receptor binding and catabolic efficiency. These models help establish causality of genetic variants in dyslipidemia.
Knock-in
Knock-in of tagged or humanized genes (e.g., APOE isoforms) allows tracking of protein localization and function in vivo. This approach is valuable for studying isoform-specific effects on lipoprotein catabolism.
Overexpression
CRISPR activation or transgenic overexpression of genes such as LPL or LDLR enhances catabolic capacity and can rescue disease phenotypes. Overexpression models are used to test therapeutic potential.
How EDITGENE Supports lipoprotein catabolic process Research
Researchers studying lipoprotein catabolic process-related genes often need to determine whether a candidate gene is causally involved in lipid clearance or whether a specific variant alters protein function. EDITGENE provides tailored CRISPR services to generate precisely engineered cell and animal models for such mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for lipoprotein catabolic process research.
Frequently Asked Questions About lipoprotein catabolic process
What is lipoprotein catabolic process?
It is the biochemical breakdown of lipoproteins, which are lipid-protein complexes that transport fats in the blood, as defined by GO:0042159.
What genes are involved in lipoprotein catabolic process?
Key genes include LPL, LDLR, APOB, APOE, ANGPTL3, ANGPTL4, ANGPTL8, LIPC, LIPG, and LIPA.
What is the GO ID for lipoprotein catabolic process?
The GO ID is GO:0042159.
How is lipoprotein catabolism regulated?
It is regulated by ANGPTL proteins, insulin, estrogens, and endosomal trafficking.
What diseases are linked to defective lipoprotein catabolism?
Atherosclerosis, familial hypercholesterolemia, hypertriglyceridemia, and lysosomal acid lipase deficiency.
What is the role of ANGPTL3 in lipoprotein catabolism?
ANGPTL3 inhibits lipoprotein lipase and endothelial lipase, reducing triglyceride clearance.
How can CRISPR be used to study lipoprotein catabolism?
CRISPR knockout, knock-in, and overexpression models allow functional testing of genes in this pathway.
What methods measure lipoprotein catabolic process?
Lipoprotein clearance assays, cellular uptake assays, RNA-seq, proteomics, and imaging.
What is the difference between lipoprotein catabolism and anabolism?
Catabolism is breakdown, while anabolism is synthesis; GO:0042159 specifically covers breakdown.
Which apolipoproteins are involved in lipoprotein catabolism?
APOB, APOE, APOC2, and APOC3 are critical for receptor binding and lipase regulation.
Conclusion
Lipoprotein catabolic process (GO:0042159) is a fundamental biological pathway that controls lipid clearance and tissue lipid delivery. Its dysregulation underlies major cardiometabolic diseases, and its components are validated therapeutic targets. CRISPR-based models and multi-omics methods provide powerful tools to dissect this process and identify new interventions. EDITGENE offers comprehensive services to support such research.
References
- 1. Sylvers-Davie KL et al.. 2021. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8.. Am J Physiol Endocrinol Metab 321(4):E493-E508 PMID: 34338039
- 2. Kockx M et al.. 2018. Triglyceride-Rich Lipoproteins.. Cardiol Clin 36(2):265-275 PMID: 29609756
- 3. Zanoni P et al.. 2018. Endocytosis of lipoproteins.. Atherosclerosis 275:273-295 PMID: 29980055
- 4. Illingworth DR. 1993. Lipoprotein metabolism.. Am J Kidney Dis 22(1):90-7 PMID: 8322800
- 5. Tikkanen MJ et al.. 2002. Lipoprotein-associated estrogens.. Cardiovasc Res 56(2):184-8 PMID: 12393088
- 7. Peng W et al.. 2025. Endosomal trafficking participates in lipid droplet catabolism to maintain lipid homeostasis.. Nat Commun 16(1):1917 PMID: 39994216
- 8. Corvilain B. 1997. [Lipoprotein metabolism].. Rev Med Brux 18(1):3-9 PMID: 9132915
